What is the role of transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) in treating addiction, including recommended protocols, safety contraindications, and efficacy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Transcranial Stimulation in Addiction Treatment

Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC) show probable efficacy for reducing craving and substance use in addiction, though clinical efficacy remains experimental and should be combined with pharmacotherapy and behavioral interventions rather than used as standalone treatment.

Current Evidence Status

The 2019 consensus guidelines from the International Network for Transcranial Electrical and Magnetic Stimulation in Addiction Medicine (INTAM) acknowledge that substance use disorder is uniquely intransigent and will likely not be solved by a single brain stimulation intervention alone 1. The field requires larger, sham-controlled studies with uniform reporting standards before definitive clinical recommendations can be made 1.

Evidence-Based Recommendations

Level B Evidence (Probable Efficacy):

  • Anodal tDCS of right DLPFC (with left DLPFC cathode) for addiction/craving 2
  • This is the highest level of recommendation currently available for brain stimulation in addiction

Meta-Analytic Findings:

  • rTMS produces medium to large effect sizes (Hedge's g > 0.5) for reducing substance use and craving 3
  • tDCS combined with medication-assisted treatment shows significant craving reduction (Hedges' g = -0.42) compared to sham 4
  • Effects are most robust with multiple stimulation sessions targeting left DLPFC 3

Recommended Protocols

Primary Target: DLPFC

77 out of 84 published studies (92%) selected DLPFC as the stimulation target 1. This is the most evidence-supported approach across all substance types.

rTMS Protocols

For Left DLPFC (most common):

  • Frequency: 10 Hz (used in 49% of studies) or 20 Hz (24% of studies) 1
  • Pulses: ≤2000 pulses per session (82% of studies) 1
  • Sessions: 8-14 sessions minimum for clinical effect; single sessions show limited benefit 1
  • Deep TMS: 10-20 Hz bilateral DLPFC stimulation for deeper penetration 1

For Right DLPFC:

  • 10-20 Hz stimulation protocols 1
  • Anodal stimulation appears most effective 2

tDCS Protocols

Standard Parameters:

  • Intensity: 2 mA (most common - 21/34 studies) 1
  • Duration: ≤20 minutes (88% of studies) 1
  • Electrode placement:
    • Anode on right DLPFC with cathode on left DLPFC, OR
    • Anode on left DLPFC with cathode on supraorbital area 1

Substance-Specific Applications

Tobacco/Nicotine

  • Level 1 evidence, Class B recommendation 5
  • Effective in 218/289 subjects across 11 studies
  • All studies conducted before standard treatment initiation 1

Alcohol

  • Level 2 evidence, Class B recommendation 5
  • Effective in 126/193 subjects across 8 studies

Cocaine

  • Level 2 evidence, Class B recommendation 5
  • Effective in 86/128 subjects across 5 studies
  • One multisite RCT (NCT03333460) using 15 Hz rTMS over left DLPFC showed promise 1

Opioids

  • Most commonly studied with methadone maintenance 4
  • Combination with medication-assisted treatment shows synergistic effects
  • Ongoing trials examining iTBS (600 pulses, 110% RMT) to DLPFC 1

Treatment Timing Considerations

Four distinct intervention windows exist 1:

  1. Before seeking treatment (all tobacco studies use this approach)
  2. Treatment-seeking but before standard treatment
  3. Within first month of standard treatment (detoxification/stabilization phase)
  4. After initial recovery (>1 month post-treatment)

Critical caveat: 40% of studies combined brain stimulation with cue exposure to enhance efficacy 1.

Outcome Measures

Primary outcomes tracked 1:

  • Craving: 76% of studies used as primary outcome (VAS most common)
  • Substance use frequency/amount: 52% of studies
  • Objective verification: Only 14 studies used urine drug tests or breath analyzers - a significant methodological weakness

Secondary outcomes:

  • Cognitive function (attention, inhibition, memory)
  • Mood symptoms (depression, anxiety, withdrawal)
  • Motivation and hedonic tone

Safety and Contraindications

The evidence documents minimal side effects with both TMS and tDCS 6. Standard TMS contraindications apply:

  • Metallic implants in head/neck
  • Seizure history (relative contraindication)
  • Cardiac pacemakers

Critical Limitations and Pitfalls

Major Methodological Weaknesses

  1. Small sample sizes: 87% of studies had ≤30 subjects per arm 1
  2. Inadequate follow-up: 71% of studies had no follow-up beyond intervention day 1
  3. Gender imbalance: 26 studies included only males; significant underrepresentation of women 1
  4. Single-session studies: 44% used only one stimulation session, which is insufficient for clinical effect 1
  5. Lack of objective verification: Most studies relied on self-report rather than biochemical confirmation 1

Clinical Practice Implications

The role of tES/TMS in daily clinical practice remains unclear 1. Current evidence suggests:

  • Not recommended as monotherapy - must be combined with pharmacotherapy and behavioral management 1
  • Requires high patient motivation due to daily treatment visits 1
  • Home-use tDCS devices may address adherence issues but raise ethical concerns about misuse 1, 2

Practical Algorithm for Implementation

If considering brain stimulation for addiction:

  1. Confirm patient has failed or partially responded to standard treatment (pharmacotherapy + behavioral therapy)

  2. Select modality based on resources:

    • rTMS: More robust evidence, larger effect sizes, requires specialized equipment
    • tDCS: Lower cost, easier administration, more variable results
  3. Target selection:

    • Primary choice: Left DLPFC (most evidence)
    • Alternative: Right DLPFC for specific protocols
    • Bilateral DLPFC: Consider for deep TMS
  4. Protocol parameters:

    • Minimum 8-14 sessions (not single sessions)
    • Consider cue exposure during or before stimulation
    • Maintenance sessions may be needed (weekly for 3 months based on smoking cessation trial) 1
  5. Combine with ongoing treatment:

    • Continue medication-assisted treatment
    • Maintain behavioral interventions
    • Monitor with objective measures (urine drug screens)
  6. Follow-up:

    • Minimum 3-month follow-up required
    • Longer-term outcomes (6-12 months) preferred but understudied

Future Directions

The field is moving toward 1:

  • Closed-loop stimulation based on real-time brain activity
  • Personalized protocols based on individual neural signatures
  • Multisite randomized controlled trials (several ongoing) 1
  • Combination protocols optimizing brain stimulation with pharmacotherapy 1, 4

Bottom line: While promising, brain stimulation for addiction remains experimental. Use only as adjunctive treatment in research settings or specialized clinics with appropriate expertise, never as standalone therapy 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.